NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Summary of Immunotherapies in Oncology:

This small group of players selected/condensed by September Neuro-Oncology Journal's: "Immunotherapy advances for glioblastoma,"

I thought I'd retype the groups here with some added information I looked up. (Note: Order below does not indicate priority, Brand Names below are either current and/or proposed by Company):

1. CTL019 is a Cellular Immunotherapeutic approach using Adoptive T-cell transfer Chimeric antigen receptor-engineered T cell. (Merck, Brand name Keytruda, possible indications: Advanced melanoma)

2. ICT-107 is a vaccination immunotherapeutic approach using Tumor-associated antigen vaccine. (Immunocellular, possible indications: Glioblastoma Multiforme)

3. IMA950 Rindopepimut (EGFRvIII) is a vaccination immunotherapeutic approach using Tumor-specific antigen vaccine. (Immatic, possible indications: Glioblastoma Multiforme)

4. DCVax is a vaccination immunotherapeutic approach using Whole tumor lysate vaccine. (Northwest Biotherapeutics, Brand Name, DCVax-L, DCVax-Direct, possible indications: All solid tumors)

5. HSPPC-96 is a vaccine therapeutic approach using HSP96 vaccine. (Agenus, Brand name, Prophage Series G-100, possible indications: Glioblastoma Multiforme)

6. Ipilimumab is an immunomodualtion therapeutic approach using Anti-CTLA-4 MAb. (Bristol-Myers-Squibb, Brand Name, Brand Name, Yervoy, Metastatic Melanoma)

7. Tremelimumab is an immunomodualtion therapeutic approach using Anti-CTLA-4 MAb. (MedImmune LLC gained worldwide rights on Tremelimumab to develop and commercialize the drug for treatment of cancer, while Pfizer retains all rights for combination therapies. possible indications: Various solid tumor cancers. )

8. Nivolumab is an immunomodualtion therapeutic approach using Anti-PD1 MAb. (Bristol-Myers-Squibb, possible indications: Solid tumor cancers. )

9. Labrolizumab is an immunomodualtion therapeutic approach using Anti-PD1 MAb. (Merck, possible indications, possible indications: Melanoma)

10. Pidilizumab is an immunomodualtion therapeutic approach using Anti-PD1 MAb. (Cure-Tech, possible indications: Hematological malignancies and solid tumors. )

11. BMS-936559 is an immunomodualtion therapeutic approach using Anti-PDL1 MAb. (Bristol-Meyer-Sqibb, possible indications: Various advanced cancers )

12. MPDL3280A is an immunomodualtion therapeutic approach using Anti-PDL1 MAb. (Genentech, possible indications: Multiple cancers types)

13. MEDI4736 is an immunomodualtion therapeutic approach using Anti-PDL1 MAb. (AstraZeneca, possible indications: Solid tumor cancer)

14. Dacluzimab is an immunomodualtion therapeutic approach using Treg-depleting reagent. (Roche, Brand Name, Zenapax, possible cancer indication: Leukemia)



Source: http://neuro-oncology.oxfordjournals.org/content/16/11/1441.full.pdf